$PAND +133% today an acquisition news
$PAND who is a clinical stage biopharmaceutical company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases just today after Merck & Co ($MRK) offer $60 per share in cash.
Here is the link of the press release.
Here is the graph of the day.
Here is the 30-day overview.